An Innovative Biotech Company
CSTEAM Biotechnology: Driving Innovation in Life Sciences
CSTEAM Biotechnology is an innovative biotech company headquartered in Dublin, Ohio, USA. Our products and services mainly include the following four areas: (1) gene and cell therapy, (2) biochips, (3) biological models, and (4) antibodies. We developed the world's first dual-target CD38 and BCMA CAR-T cell therapy for multiple myeloma and achieved good results. We also developed autologous young stem cell therapy based on gene editing technology for chronic diseases such as liver fibrosis and pulmonary fibrosis. In addition, we are at the forefront of biochip innovation with the development of circular RNA (circRNA) and functional RNA products based on Lab-on-a-Chip (LOC) technology. In terms of biological models, we have generated a variety of organoids and mouse models that are highly similar to human diseases, which have been applied to scientific research, drug discovery and drug development. Our mission is to enhance the treatment efficiency of difficult diseases by developing innovative gene and cell therapies, using biochip technology to improve the diagnostic accuracy of diseases, and providing valuable biological models and antibody products for scientific research, drug discovery and drug development through gene editing and antibody engineering technologies. CSTEAM Biotechnology is committed to establishing partnerships with universities, research institutions, hospitals and pharmaceutical companies to actively develop breakthrough biotechnology products that can benefit mankind. Lab-on-a-Chips, Organoids, Exosomes, RNAs
Products and Services
Antibodies
-
Monoclonal antibodies are specific proteins from a single B cell clone, used in diagnostics and therapies for their precision.
-
Polyclonal antibodies, produced by various B cell clones, recognize multiple epitopes, enhancing adaptability and binding strength, beneficial in research and diagnostics.
-
Genetically engineered antibodies, including chimeric, humanized, and fully human types, are created using recombinant DNA technology, offering enhanced effectiveness, stability, and reduced immunogenicity for therapeutic and diagnostic applications.
Biochips
-
Biochips, such as DNA and protein microarrays, cellular and tissue microarrays, electrochemical, and optical biochips, analyze genetic variations, protein interactions, cell behavior, and tissue samples, useful in genomics, proteomics, cancer research, diagnostics, and biosensing.
-
Liquid biochips, including lab-on-a-chip, droplet-based microfluidics, paper-based microfluidic devices, and hydrogel-based biochips, facilitate biochemical reactions in liquid environments, aiding point-of-care diagnostics, single-cell analysis, field diagnostics, and tissue engineering.
-
These advancements enhance biomedical research, diagnostics, and personalized medicine.
Biological Models
-
Cellular models, including primary cells and immortalized cell lines, facilitate studies on gene function and drug screening.
-
Organoid models, derived from stem cells, replicate organ structure and function, advancing insights into development, disease mechanisms, and personalized medicine.
-
Animal models, such as mice and zebrafish, provide whole-organism perspectives on genetics, physiology, and pathology.
-
These models are essential for understanding biological processes, developing treatments, and evaluating drug safety and efficacy, bridging the gap between in vitro studies and clinical applications.
Gene and Cell Therapies
-
Gene therapy modifies or introduces genes to correct genetic defects or enhance cell functions, used in treatments for inherited disorders like cystic fibrosis and making cells HIV-resistant.
-
Cell therapy involves administering living cells to restore function or combat diseases, including stem cell transplants for blood disorders and CAR T-cell therapy for cancer.
-
These therapies leverage cutting-edge technology to offer new solutions for previously untreatable conditions, advancing personalized medicine by tailoring treatments to individual patient needs.
We are excited to announce that CSTEAM Biotechnology has been officially recognized by the HCA Executive Office as a member of the prestigious Human Cell Atlas (HCA) program! This recognition marks a major milestone for our team as we join a global initiative dedicated to mapping every cell in the human body to advance our understanding of health and disease.
As part of our contribution to the HCA program, CSTEAM Biotechnology will focus on developing innovative devices that model the complex interactions between cells and between cells and their surrounding environment. These cutting-edge technologies will play a key role in supporting the HCA's mission to create a comprehensive cellular reference atlas, driving breakthroughs in biomedical research and personalized medicine.
We are honored to be a part of this revolutionary project and look forward to working with the global HCA community to push the boundaries of science.
